[1]马云飞,孙旭,杨永,等.乳腺癌的中医证型及用药规律研究[J].西部中医药,2017,30(01):46-48.
　MA Yunfei,SUN Xu,YANG Yong,et al.Study on TCM Syndrome and Medication Rule of Breast Cancer[J].Western Journal of Traditional Chinese Medicine,2017,30(01):46-48.
点击复制

乳腺癌的中医证型及用药规律研究()
分享到：

《西部中医药》[ISSN:2096-9600/CN:62-1204/R]

卷:
30
期数:
2017年01期
页码:
46-48
栏目:
出版日期:
2017-01-15

文章信息/Info

Title:
Study on TCM Syndrome and Medication Rule of Breast Cancer
文章编号:
1004-6852(2017)01-0046-03
作者:
马云飞1，孙旭1，杨永2，念家云2，孟慧2，于明薇1，王笑民1△
1 首都医科大学附属北京中医医院，北京 100010； 2 北京中医药大学
Author(s):
MA Yunfei1, SUN Xu1, YANG Yong2, NIAN Jiayun2, MENG Hui2, YU Mingwei1, WANG Xiaomin1△
1 Beijing TCM Hospital, Capital Medicine University, Beijing 100010, China; 2 Beijing University of Chinese Medicine
关键词:
乳腺癌; 中医证候; 用药规律
Keywords:
breast cancer;  TCM syndrome;  medication rule
分类号:
R737.19
文献标志码:
A
摘要:
目的：探讨乳腺癌的中医证型分布及用药规律。方法：检索2000—2015年中国期刊全文数据库、维普数据库、万方数据库关于中医药治疗乳腺癌的相关文献，提取纳入文献的中医证候及用药信息，进行统一规范化处理后，建立乳腺癌中医治疗数据库，对其临床证候类型及用药情况进行相关频次分析。结果：纳入的45篇中医药治疗乳腺癌的文献中，中医证型主要为肝郁型、痰瘀毒热型、气血两虚型、冲任失调型、气阴两虚型，所占比例依次为48.4%、18.8%、15.6%、14.1%、3.1%；中药治疗乳腺癌的高频药物中归肝经的药物频率达33.3%。结论：在中医药辅助治疗乳腺癌的过程中从肝论治占主导地位。
Abstract:
Objective: To explore TCM syndrome and medication rule of breast cancer. Methods: Relevant documents of TCM in treating breast cancer in CNKI, CQVIP and WanFang Data were retrieved from the year of 2000 to 2015. TCM syndromes and medication information in documents were extracted. Database of TCM in treating breast cancer were built after united and standardized management. Relevant frequency of clinical TCM syndrome and medication condition was analyzed. Results: All 45 documents of TCM in treating breast cancer were incorporated at last, TCM syndromes can be divided into liver-stagnation type, phlegm-stasis type, Qi and blood deficiency type, incoordination between the Chong and Ren meridians type, Qi and Yin deficiency type, the rates were 48.4%, 18.8%, 15.6%, 14.1% and 3.1% in turn. The frequent rate of high-frequency medicines belonged to liver meridian in Chinese herbs for breast cancer reached to 33.3%. Conclusion: Treatment starting from liver occupies dominant status in the process of TCM in treating breast cancer.

相似文献/References:

[1]王斌,王艳杰,梁贵文,等.乳积方防治乳腺癌患者术后复发转移的临床研究*[J].西部中医药,2013,26(08):101.
　WANG Bin,WANG Yanjie,LIANG Guiwen,et al.Clinical Study on RuJiFang to Prevent Postoperative Recurrence and Metastasis of Breast Cancer[J].Western Journal of Traditional Chinese Medicine,2013,26(01):101.
[2]侯俊明,江静.疏肝解郁法联合化疗治疗乳腺癌临床疗效分析[J].西部中医药,2014,27(09):1.
[3]王丽,何丽娟,朱玉芹.循证护理对乳腺癌化疗患者自尊水平和应对方式的影响[J].西部中医药,2014,27(11):134.
[4]朱慧华.纽曼护理对乳腺癌手术患者心理健康和生活质量的影响[J].西部中医药,2014,27(12):105.
[5]周涛,何彪,霍利,等.不同证型冠心病患者螺旋CT冠状动脉CTA影像分析[J].西部中医药,2015,28(02):130.
[6]张晓华,张晓岚△,梁玉荣,等.综合心理干预对乳腺癌化疗患者医学应对方式及生命质量的影响[J].西部中医药,2015,28(07):123.
[7]谷雨,华海清△.中医辨证分型与乳腺癌预后的相关性研究[J].西部中医药,2015,28(04):85.
[8]刘琛,吴黎雅,赵红佳,等.人参养荣汤干预乳腺癌新辅助化疗所致气血两虚证的临床研究[J].西部中医药,2011,24(11):3.
[9]李树建.扶正祛积汤联合CEF化疗方案治疗晚期乳腺癌40例临床研究[J].西部中医药,2013,26(09):1.
　LI Shujian.Clinical Study on FuZheng QuJiTang Combined with CEF Chemotherapy in Treating 40 Patients Suffering from Advanced Mammary Cancer[J].Western Journal of Traditional Chinese Medicine,2013,26(01):1.
[10]安妮,杨俊兰.消 疒徵祛积方联合化疗对晚期乳腺癌患者血清CEA、CA125、CA153和CA19-9含量及临床疗效的影响[J].西部中医药,2013,26(03):7.
　AN Ni,YANG Junlan.Effects of XiaoZhen QuJiFang and Chemotherapy on Clinical Efficacy and Contents of Serum CEA, CA125, CA153 and CA19-9 of Patients with Mammary Cancer at Advanced Stage[J].Western Journal of Traditional Chinese Medicine,2013,26(01):7.
[11]孔咏霞.乳腺癌中医证型与证候要素分布规律文献研究[J].西部中医药,2018,31(03):68.
　KONG Yongxia.Literature Research on Distribution Laws of Syndrome Elements and TCM Patterns of Breast Cancer[J].Western Journal of Traditional Chinese Medicine,2018,31(01):68.

备注/Memo

备注/Memo:
收稿日期：2016-02-27 *基金项目：国家自然科学基金资助项目(编号81473643)；北京市科技计划课题(编号D161100005116005)；北京市医院管理局青年人才培养“青苗”计划(编号QML20150903)。作者简介：马云飞(1990—)，女，在读硕士研究生。研究方向：肿瘤的中西医结合诊治。 △通讯作者：王坚民(1965—)，男，博士学位，主任医师。研究方向：肿瘤的中西医结合诊治。
更新日期/Last Update: 2017-01-15